PIKFYVE

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Monday, November 13, 2023
LLP, Workforce, Innovation, News, Pomerantz, PIKFYVE

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Enovix Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023
Internet of things, Meditech, FDA, Intelligence, Smartphone, Patent, Temperature, Walmart, Innovation, Public expenditure, Architecture, Micrometre, GAAP, Original equipment manufacturer, Acquisition, Cell, Engineering, Piping Technology and Products, Learning, FAT, Autoline Detroit, Ecosystem, Electronics, Graphite, CVS, McKinsey & Company, Anxiety, Investment, Silicon, Rare-earth element, Fine chemical, Electric battery, Mobile phone, Video game, Beauty salon, Bank, Walgreens, PIKFYVE, Qualcomm, Lenovo, United States Army

FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, announced today financial results for the third quarter of 2023, which included the summary below from its President and CEO, Dr. Raj Talluri.

Key Points: 
  • FREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Enovix Corporation (“Enovix”) (Nasdaq: ENVX), an advanced silicon battery company, announced today financial results for the third quarter of 2023, which included the summary below from its President and CEO, Dr. Raj Talluri.
  • Our GAAP operating expenses of $33.8 million in the third quarter of 2023 were down from $37.7 million in the second quarter of 2023.
  • Our non-GAAP operating expenses of $18.8 million in the third quarter of 2023 were down from $19.9 million in the first quarter of 2023.
  • Enovix will hold a video conference call at 2:00 PM PT / 5:00 PM ET today, November 7, 2023, to discuss the company’s business updates and financial results.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Sunday, November 5, 2023
Innovation, Workforce, News, Pomerantz, LLP, Private investigator, PIKFYVE

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Morris Kandinov Investigating ARDX, LESL, ENVX, and FATE; Shareholders are Encouraged to Contact the Firm

Retrieved on: 
Thursday, November 2, 2023
FDA, Sale, Complaint, Cybook Gen1, Constipation, Food, Tax, Workforce, News, Destiny, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Dialysis, Executive, New Drug Application, SAN, Depreciation, CKD, NDA, Rodgers, Therapy, Patient, Letter, Pharmaceutical industry, PIKFYVE

Morris Kandinov is investigating Ardelyx, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

Key Points: 
  • Morris Kandinov is investigating Ardelyx, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Leslie’s, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Enovix Corporation regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.
  • Morris Kandinov is investigating Fate Therapeutics, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Friday, October 27, 2023
Innovation, Workforce, News, Pomerantz, LLP, Private investigator, PIKFYVE

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Thursday, October 19, 2023
Innovation, Workforce, News, Pomerantz, LLP, Private investigator, PIKFYVE

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Enovix Corporation Investors: Company Investigated by the Portnoy Law Firm

Retrieved on: 
Wednesday, October 11, 2023
Mayo Clinic Center for Innovation, News, Workforce, Innovation, PIKFYVE

​LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Enovix Corporation ("Enovix" or the "Company") (NASDAQ: ENVX) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Enovix stock. Enovix investors are encouraged to contact the firm to discuss their legal rights.

Key Points: 
  • ​LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Enovix Corporation ("Enovix" or the "Company") (NASDAQ: ENVX ) investors that the law firm has initiated an investigation on behalf of investors that lost money on their Enovix stock.
  • Enovix investors are encouraged to contact the firm to discuss their legal rights.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Wednesday, October 11, 2023
Pomerantz, LLP, Innovation, Workforce, News, Private investigator, PIKFYVE

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation - ENVX

Retrieved on: 
Tuesday, October 3, 2023
Workforce, LLP, Innovation, Pomerantz, News, Private investigator, PIKFYVE

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).

Key Points: 
  • NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Enovix Corporation (“Enovix” or the “Company”) (NASDAQ: ENVX).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Enovix and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Enovix Announces Strategic Realignment of Fab1 to Improve Operational Efficiency and Enhance Technology Development

Retrieved on: 
Tuesday, October 3, 2023
Workforce, Learning, Smartphone, Internet of things, Wearable, Mayo Clinic Center for Innovation, Innovation, Research, Cell, Silicon, GEN1, Holliday junction 5' flap endonuclease, Agility, United States Department of the Army, Engineering, Depreciation, R, Mobile phone, Fine chemical, PIKFYVE

This move is supportive of the Company’s strategy to locate high-volume manufacturing in Asia near customers and suppliers while locating technology development in both Silicon Valley and Asia.

Key Points: 
  • This move is supportive of the Company’s strategy to locate high-volume manufacturing in Asia near customers and suppliers while locating technology development in both Silicon Valley and Asia.
  • Enovix expects this restructuring to be completed during the fourth quarter of 2023 and result in annualized savings of approximately $22 million.
  • In 2024, Fab1 will shift to housing the R&D Agility Line and will be used for new technology development, materials research, process engineering, and customer sampling.
  • Enovix also plans to add dry room space at Fab1 for battery prototyping work to support engagements with Automotive OEMs.